nach oben

Current Treatment Options in Cardiovascular Medicine

Erschienen in:

01.11.2018 | Imaging (Q Truong, Section Editor)

Coronary Artery Calcium: Recommendations for Risk Assessment in Cardiovascular Prevention Guidelines

verfasst von: Mahmoud Al Rifai, MD MPH, Miguel Cainzos-Achirica, MD MPH, Sina Kianoush, MD MPH, Mohammadhassan Mirbolouk, MD, Allison Peng, BS, Josep Comin-Colet, MD PhD, Michael J. Blaha, MD MPH

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

In this review, we evaluate the coronary artery calcium (CAC) score as a biomarker for advanced atherosclerotic cardiovascular disease (ASCVD) risk assessment.

Recent findings

We summarize the evidence from multiple epidemiological studies, which show a clear advantage of CAC compared to traditional and non-traditional cardiovascular risk factors. We then compare the recommendations included in the 2013 American College of Cardiology/American Heart Association (ACC/AHA) and in the 2017 Society of Cardiovascular Computed Tomography (SCCT) guidelines for the use of CAC in ASCVD risk assessment, and examine the recent 2018 US Preventive Services Task Force (USPSTF) document. Finally, based on the currently available evidence, we provide constructive input for the upcoming ACC/AHA guidelines, regarding the population in whom CAC is most likely to be informative, the level of evidence that we believe should be assigned to CAC as an advanced ASCVD risk assessment tool, and the special populations in whom CAC might be beneficial for further risk assessment.

Summary

We support a pragmatic approach that combines the pooled cohort equations (PCE) for initial ASCVD risk stratification, followed by CAC for refining ASCVD risk assessment among a broad range of intermediate risk patients and other special groups.

Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2935–59.CrossRef

Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013; published online Nov 7. doi:https://doi.org/10.1016/j.jacc.2013.11.002.CrossRef

Blaha MJ, Dardari ZA, Blumenthal RS, Martin SS, Nasir K, Al-Mallah MH. The new ‘intermediate risk’ group: a comparative analysis of the new 2013 ACC/AHA risk assessment guidelines versus prior guidelines in men. Atherosclerosis. 2014;237:1–4.CrossRef

Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2010;122:2748–64.CrossRef

Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. J Am Coll Cardiol. 2010;56:1397–406.CrossRef

Blankstein R, Budoff MJ, Shaw LJ, Goff DC Jr, Polak JF, Lima J, et al. Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2011;58:364–74.CrossRef

Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684–92.CrossRef

Möhlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57:1455–64.CrossRef

Rozanski A, Gransar H, Shaw LJ, Kim J, Miranda-Peats L, Wong ND, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing. J Am Coll Cardiol. 2011;57:1622–32.CrossRef

10.

Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95.CrossRef

11.

Tota-Maharaj R, Blaha MJ, McEvoy JW, et al. Coronary artery calcium for the prediction of mortality in young adults <45 years old and elderly adults >75 years old. Eur Heart J. 2012;33:2955–62.CrossRef

12.

Amin NP, Martin SS, Blaha MJ, Nasir K, Blumenthal RS, Michos ED. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol. 2014;63:2789–94.CrossRef

13.

Cainzos-Achirica M, Desai CS, Wang L, Blaha MJ, Lopez-Jimenez F, Kopecky SL, et al. Pathways forward in cardiovascular disease prevention one and a half years after publication of the 2013 ACC/AHA cardiovascular disease prevention guidelines. Mayo Clin Proc. 2015;90:1262–71.CrossRef

14.

Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72:434–47.CrossRef

15.

Hecht H, Blaha MJ, Berman DS, Nasir K, Budoff M, Leipsic J, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2017;11:157–68.CrossRef

16.

Curry SJ, Krist AH, Owens DK, et al. Risk assessment for cardiovascular disease with nontraditional risk factors. JAMA. 2018;320:272.CrossRef

17.

Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–45.CrossRef

18.

Sung J, Yeboah J, Lee J, Smith C, Terry J, Sims M, et al. Diagnostic value of coronary artery calcium score for cardiovascular disease in African Americans: the Jackson heart study. Br J Med Med Res. 2016;11:1–9.CrossRef

19.

LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162:421–9.CrossRef

20.

Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43:1663–9.CrossRef

21.

Paixao ARM, Ayers CR, El Sabbagh A, et al. Coronary artery calcium improves risk classification in younger populations. JACC Cardiovasc Imaging. 2015;8:1285–93.CrossRef

22.

Carr JJ, Jacobs DR, Terry JG, et al. Association of Coronary Artery Calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391–9.CrossRef

23.

Elias-Smale SE, Wieberdink RG, Odink AE, Hofman A, Hunink MGM, Koudstaal PJ, et al. Burden of atherosclerosis improves the prediction of coronary heart disease but not cerebrovascular events: the Rotterdam study. Eur Heart J. 2011;32:2050–8.CrossRef

24.

• Silverman MG, Blaha MJ, Krumholz HM, Budoff MJ, Blankstein R, Sibley CT, et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the multi-ethnic study of atherosclerosis. Eur Heart J. 2014;35:2232–41. This study demonstrated the heterogeneity between risk factor burden and CAC and showed the individuals with no risk factors and high CAC had a higher risk of CHD compared to those with 3 or more risk factors and absent CAC.CrossRef

25.

Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014;129:77–86.CrossRef

26.

Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004;164:1285–92.CrossRef

27.

• Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139–47. This study showed the CAC was superior to other non-traditional risk factors such as arterial-brachial index, high-sensitivity C-reactive protein (hsCRP) levels, and family history (FH) of ASCVD for the prediction and discrimination of incident ASCVD when added to the pooled cohort equations.CrossRef

28.

Yeboah J, Polonsky TS, Young R, McClelland RL, Delaney JC, Dawood F, et al. Utility of non-traditional risk markers in individuals ineligible for statin therapy according to the 2013 ACC/AHA cholesterol guidelines. Circulation. 2015;132:916–22.CrossRef

29.

•• Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133:849–58. This study showed that absent CAC (CAC = 0) resulted in the greatest downward shift of estimated ASCVD risk compared to other negative risk markers including carotid intima-media thickness < 25th percentile, absence of carotid plaque, brachial flow-mediated dilation > 5% change, ankle-brachial index > 0.9 and < 1.3, high-sensitivity C-reactive protein < 2 mg/L, homocysteine < 10 μmol/L, N-terminal pro-brain natriuretic peptide < 100 pg/mL, no microalbuminuria, no family history of coronary heart disease (any/premature), absence of metabolic syndrome, and healthy lifestyle.CrossRef

30.

•• Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66:1657–68. This study showed that there was significant heterogeneity in ASCVD risk based on CAC among individuals recommended for statins according to the 2013 ACC/AHA guidelines. The absence of CAC resulted in reclassifion of approximately half of candidates as not eligible for statin therapy.CrossRef

31.

Peters SAE, den Ruijter HM, Bots ML, Moons KGM. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart. 2012;98:177–84.CrossRef

32.

DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266–75.CrossRef

33.

Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator. JAMA Intern Med. 2014;174:1964–71.CrossRef

34.

Bittencourt MS, Blankstein R, Blaha MJ, et al. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study. Eur J Prev Cardiol. 2018;204748731878893.

35.

Hecht HS, Cronin P, Blaha MJ, Budoff MJ, Kazerooni EA, Narula J, et al. 2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. J Cardiovasc Comput Tomogr. 2017;11:74–84.CrossRef

36.

Karmali KN, Goff DC, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959–68.CrossRef

37.

Tota-Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, et al. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. Mayo Clin Proc. 2014;89:1350–9.CrossRef

38.

• Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize acc/aha-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68:881–91. This study showed that elderly individuals without CAC are unlikely to benefit from statins given low ASCVD event rates. These individuals would therefore not benefit from statins.CrossRef

39.

Miedema MD, Dardari ZA, Kianoush S, Virani SS, Yeboah J, Knickelbine T, et al. Statin eligibility, coronary artery calcium, and subsequent cardiovascular events according to the 2016 United States Preventive Services Task Force (USPSTF) statin guidelines: MESA (multi-ethnic study of atherosclerosis). J Am Heart Assoc. 2018;7:e008920.CrossRef

40.

Wilkins JT, Lloyd-Jones DM. USPSTF recommendations for assessment of cardiovascular risk with nontraditional risk factors. JAMA. 2018;320:242–4.CrossRef

41.

Polonsky TS, Greenland P. Viewing the value of coronary artery calcium testing from different perspectives. JAMA Cardiol. 2018;published online July 10. doi:https://doi.org/10.1001/jamacardio.2018.2199.CrossRef

42.

McEvoy JW, Martin SS, Blaha MJ, et al. The case for and against a coronary artery calcium trial. JACC Cardiovasc Imaging. 2016;9:994–1002.CrossRef

43.

Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, et al. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines. JACC Cardiovasc Imaging. 2017;10:938–52.CrossRef

44.

Silva Ferreira A, De Araujo GP, Marques H, Cardim N, Machado FP. Coronary artery calcium score to guide statin therapy in patients with elevated C-reactive protein and low LDL cholesterol levels: a cost-effectiveness analysis. Eur Heart J. 2013;34:P692.CrossRef

45.

Roberts ET, Horne A, Martin SS, Blaha MJ, Blankstein R, Budoff MJ, et al. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the multi-ethnic study of atherosclerosis (MESA). PLoS One. 2015;10:e0116377.CrossRef

46.

Blaha MJ, Nasir K, Blumenthal RS. Statin therapy for healthy men identified as “increased risk”. JAMA. 2012;307:1489–90.CrossRef

47.

Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7:453–60.CrossRef

48.

McEvoy JW, Martin SS, Dardari ZA, et al. Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. Circulation. 2016. http://circ.ahajournals.org/content/early/2016/11/23/CIRCULATIONAHA.116.025471. Accessed 6 April 2017.

49.

Cainzos-Achirica M, Di Carlo PA, Handy CE, et al. Coronary artery calcium score: the mammogram of the heart? Curr Cardiol Rep. 2018;20:70.CrossRef

50.

Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (chronic renal insufficiency cohort) study. Am J Kidney Dis. 2011;58:519–26.CrossRef

51.

Hsue PY, Squires K, Bolger AF, Capili B, Mensah GA, Temesgen Z, et al. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation. 2008;118:e41–7.CrossRef

52.

Giles JT, Szklo M, Post W, Petri M, Blumenthal RS, Lam G, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the multi-ethnic study of atherosclerosis. Arthritis Res Ther. 2009;11:R36.CrossRef

53.

Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407–15.CrossRef

54.

Shah NP, Cainzos-Achirica M, Feldman DI, Blumenthal RS, Nasir K, Miner MM, et al. Cardiovascular disease prevention in men with vascular erectile dysfunction: the view of the preventive cardiologist. Am J Med. 2016;129:251–9.CrossRef

55.

Feldman DI, Cainzos-Achirica M, Billups KL, DeFilippis AP, Chitaley K, Greenland P, et al. Subclinical vascular disease and subsequent erectile dysfunction: the multiethnic study of atherosclerosis (MESA). Clin Cardiol. 2016;39:291–8.CrossRef

56.

Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the multiethnic study of atherosclerosis study. JACC Cardiovasc Imaging. 2012;5:358–66.CrossRef

57.

Al Rifai M, Silverman MG, Nasir K, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2015;239:629–33.CrossRef

58.

Patel J, Al Rifai M, Scheuner MT, et al. Basic vs more complex definitions of family history in the prediction of coronary heart disease: the multi-ethnic study of atherosclerosis. Mayo Clin Proc 2018;Published online March 16. doi:https://doi.org/10.1016/j.mayocp.2018.01.014.CrossRef

59.

Ali SS, Oni ET, Warraich HJ, Blaha MJ, Blumenthal RS, Karim A, et al. Systematic review on noninvasive assessment of subclinical cardiovascular disease in obstructive sleep apnea: new kid on the block! Sleep Med Rev. 2014;18:379–91.CrossRef

60.

Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis. Circulation. 2018;CIRCULATIONAHA.118.033990.

61.

Blaha M, Budoff MJ, Shaw LJ, Khosa F, Rumberger JA, Berman D, et al. Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging. 2009;2:692–700.CrossRef

62.

Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal coronary calcification: the multi-ethnic study of atherosclerosis (MESA). Am Heart J. 2009;158:554–61.CrossRef

63.

Min JK, Lin FY, Gidseg DS, Weinsaft JW, Berman DS, Shaw LJ, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the ‘warranty period’ for remaining normal? J Am Coll Cardiol. 2010;55:1110–7.CrossRef

64.

Al Rifai M, Cainzos-Achirica M, Blaha MJ. Establishing the warranty of a coronary artery calcium score of zero. Atherosclerosis. 2015;238:1–3.CrossRef

65.

Silverman MG, Harkness JR, Blankstein R, Budoff MJ, Agatston AS, Carr JJ, et al. Baseline subclinical atherosclerosis burden and distribution are associated with frequency and mode of future coronary revascularization: multi-ethnic study of atherosclerosis. JACC Cardiovasc Imaging. 2014;7:476–86.CrossRef

66.

Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–82.CrossRef

67.

Martin SS, Sperling LS, Blaha MJ, Wilson PWF, Gluckman TJ, Blumenthal RS, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. J Am Coll Cardiol. 2015;65:1361–8.CrossRef

68.

Michos ED, Blaha MJ, Blumenthal RS. Use of the coronary artery calcium score in discussion of initiation of statin therapy in primary prevention. Mayo Clin Proc. 2017;92:1831–41.CrossRef

Titel: Coronary Artery Calcium: Recommendations for Risk Assessment in Cardiovascular Prevention Guidelines
verfasst von: Mahmoud Al Rifai, MD MPH
Miguel Cainzos-Achirica, MD MPH
Sina Kianoush, MD MPH
Mohammadhassan Mirbolouk, MD
Allison Peng, BS
Josep Comin-Colet, MD PhD
Michael J. Blaha, MD MPH
Publikationsdatum: 01.11.2018
Verlag: Springer US
Erschienen in: Current Treatment Options in Cardiovascular Medicine / Ausgabe 11/2018
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI: https://doi.org/10.1007/s11936-018-0685-0

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Sex Differences in the Management of Advanced Heart Failure

Disparities in Cardiac Care of Women: Current Data and Possible Solutions

Imaging and Management of Heart Failure and Preserved Ejection Fraction